本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 证券代码：002688 证券简称：金河生物 公告编号：2025-015 金河生物科技股份有限公司 第六届董事会第二十四次会议决议公告 金河生物科技股份有限公司（以下简称"公司"）第六届董事会第二十四次 会议于 2025 年 4 月 9 日以电子邮件方式发出通知，并于 2025 年 4 月 18 日以通 讯方式召开，会议由董事长王东晓先生主持，应到董事 9 人，实到董事 9 人，本 次董事会出席会议董事人数符合法律法规，会议合法有效。会议召开符合《中华 人民共和国公司法》等法律、法规和《公司章程》的规定。与会董事以通讯表决 的方式审议通过了以下议案： 一、以 9 票同意，0 票反对，0 票弃权审议通过了《关于变更公司注册资本 及修订<公司章程>部分条款的议案》。 本议案需提交 2025 年第二次临时股东大会审议。 具体内容详见公司同日于巨潮资讯网（http://www.cninfo.com.cn）及《证 券时报》、《中国证券报》、《证券日报》和《上海证券报》披露的《关于变更 公司注册资本及修订<公司章程 ...

金河生物科技股份有限公司章程 金河生物科技股份有限公司 章 程 （二〇二五年四月修订） | 第一章 总则 3 | | --- | | 第二章 经营宗旨和范围 4 | | 第三章 股份 4 | | 第一节 股份发行 4 | | 第二节 股份增减和回购 7 | | 第三节 股份转让 8 | | 第四章 股东和股东大会 9 | | 第一节 股东 9 | | 第二节 股东大会的一般规定 11 | | 第三节 股东大会的召集 14 | | 第四节 股东大会的提案与通知 15 | | 第五节 股东大会的召开 17 | | 第六节 股东大会的表决和决议 19 | | 第五章 董事会 24 | | 第一节 董事 24 | | 第二节 董事会 27 | | 第六章 总经理及其他高级管理人员 31 | | 第七章 监事会 32 | | 第一节 监事 32 | | 第二节 监事会 33 | | 第八章 财务会计制度、利润分配和审计 34 | | 第一节 财务会计制度 34 | | 第二节 内部审计 37 | | 第三节 会计师事务所的聘任 37 | | 第九章 通知和公告 38 | | 第一节 通知 38 | | 第二节 公告 3 ...

这几只票暗盘资金正在偷偷流入，立即查看>> 养殖业板块震荡走低，金河生物（002688）跌超9%，晓鸣股份（300967）、回盛生物（300871）、华 英农业（002321）、罗牛山（000735）、神农集团（605296）等跟跌。 ...

深交所公开信息显示，当日该股因日跌幅偏离值达-8.47%上榜，营业部席位合计净卖出4394.91万元。 金河生物今日下跌7.32%，全天换手率27.70%，成交额14.52亿元，振幅8.27%。龙虎榜数据显示，营业 部席位合计净卖出4394.91万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交2.22亿元，其中，买入成交额为8908.12 万元，卖出成交额为1.33亿元，合计净卖出4394.91万元。 具体来看，今日上榜营业部中，第一大买入营业部为东方财富证券股份有限公司拉萨东环路第二证券营 业部，买入金额为2119.44万元，第一大卖出营业部为中国银河证券股份有限公司成都益州大道证券营 业部，卖出金额为3067.74万元。 近半年该股累计上榜龙虎榜5次，上榜次日股价平均涨0.64%，上榜后5日平均涨3.36%。 卖五 平安证券股份有限公司四川分公司 281.43 1483.75 （文章来源：证券时报网） 资金流向方面，今日该股主力资金净流出6037.10万元，其中，特大单净流出984.63万元，大单资金净流 出5052.47万元。近5日主力资金净流出7.80亿元。（数据宝） 金河生物4月14 ...

Investment Rating - The industry investment rating is "Overweight" indicating that the agricultural sector is expected to outperform the overall market [2][5]. Core Insights - The report emphasizes the strategic value of the agricultural sector under the backdrop of unexpected tariff policies and the "internal circulation + self-control" approach, highlighting investment opportunities across various sub-sectors [5][3]. - The report notes a significant increase in online sales of pet food, with March sales reaching 2.65 billion yuan, a year-on-year increase of 23% and a month-on-month increase of 44% [3][5]. Summary by Relevant Sections Agricultural Sector Performance - The Shenwan Agricultural Index rose by 3.3%, while the CSI 300 Index fell by 2.9% during the week [3][4]. - Top five gainers included Shen Nong Technology (35.7%), Xin Sai Co. (32.2%), Jin He Biological (28.8%), Wanxiang De Nong (24.9%), and Bei Da Huang (19.7%) [4][12]. Livestock Farming - Swine prices are expected to fluctuate, with the average price for external three yuan pigs at 14.80 yuan/kg, a week-on-week increase of 1.4% [3][13]. - The report anticipates a potential decline in pig prices due to increased supply in the second quarter, suggesting a left-side investment opportunity in the sector [3][5]. Poultry Farming - The price of white chicken chicks continues to weaken, with the average price at 2.54 yuan/chick, a week-on-week decrease of 7.64% [3][5]. - The report highlights the importance of monitoring consumer demand, particularly in the restaurant and catering sectors, as a key factor affecting the poultry market [3][5]. Pet Food Industry - The report indicates that domestic brands are likely to gain market share as the cost-effectiveness of imported pet food declines [5][3]. - Key companies in the pet food sector, such as Guai Bao Pet and Zhong Chong Co., reported significant growth in sales, with Guai Bao Pet achieving a 47% year-on-year increase in March [3][5]. Seed Industry - The necessity for self-control in the seed industry is increasingly evident, with a push towards biological breeding and accelerated industrialization [5][3]. - The report recommends focusing on companies like Longping High-Tech and Dabeinong in the seed sector [5][3].

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 半导体板块爆发 半导体板块今日大幅拉升，截至收盘，晶华微、唯捷创芯、富满微、纳芯微、圣邦股份、思瑞浦等20% 涨停，华虹公司涨19.75%。 在全球股市普遍走低背景下，A股、港股逆市走高。 今日，在隔夜美股大跌后，亚太市场普遍走低，日经225指数一度跌超5%。欧股今日开盘后也迅速走 低，截至发稿，主要指数均转跌，德国DAX指数、意大利富时MIB指数、欧元区斯托克50指数跌幅均 超1%。 | 英国富时100 | 7883.60 | -29.65 | -0.37% | | --- | --- | --- | --- | | 法国CAC40 | 7088.53 | -37.49 | -0.53% | | 德国DAX | 20341.84 | -220.89 | -1.07% | | 意大利富时MIB | 33779.85 | -497.24 | -1.45% | | 欧元区STOXX50(欧元) | 4762.53 d | -56.39 | -1.17% | A股、港股今日逆市走高。A股创业板指、科创50指数等较为强势；港股午后再度拉升，恒生 ...

Group 1 - The grain concept sector experienced a decline of 4.68%, ranking among the top declines in concept sectors, with stocks like Wanxiang Deno, Jinhai Biological, and Beidahuang hitting the daily limit down [1][2] - Major stocks within the grain concept that saw significant declines include Shennong Seed Industry and Dunhuang Seed Industry, while a few stocks like Yuanda Holdings and Guangyu Group saw increases of 10.07% [1][2] - The grain concept sector faced a net outflow of 1.798 billion yuan from main funds, with 36 stocks experiencing outflows, and 8 stocks seeing outflows exceeding 100 million yuan, led by Beidahuang with a net outflow of 247 million yuan [2][3] Group 2 - The top stocks with the largest net outflows in the grain concept include Beidahuang, Jinjian Rice Industry, and Jinhai Biological, with net outflows of 247 million yuan, 199 million yuan, and 158 million yuan respectively [2][3] - Conversely, stocks with the largest net inflows include Guangyu Group, Yuanda Holdings, and Kemin Food, with net inflows of 37.87 million yuan, 27.89 million yuan, and 6.12 million yuan respectively [2][3] - The overall trading activity in the grain concept sector showed a significant turnover rate, with stocks like Jinhai Biological and Beidahuang having turnover rates of 19.94% and 11.20% respectively [3]

Group 1 - The aquaculture sector continues to decline, with Jinhe Biology (002688) nearing a trading halt [1] - Other companies such as Xiangjia Co., Ltd. (002982), Xiaoming Co., Ltd. (300967), Fucheng Co., Ltd. (600965), and Huaying Agriculture (002321) are also experiencing declines [1] - Dark pool funds are flowing into these stocks, indicating potential interest from institutional investors [1]

证券代码：002688 证券简称：金河生物 公告编号：2025-014 金河生物科技股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 一、股票交易异常波动的情况介绍 金河生物科技股份有限公司（以下简称"公司"）股票（股票简称：金河生 物，股票代码：002688）交易价格于2025年4月8日、4月9日、4月10日连续三个 交易日收盘价格涨幅偏离值累计25.05%，根据深圳证券交易所的相关规定，属于 股票交易的异常波动情形。 二、公司关注并核实的情况 四、公司认为必要的风险提示 针对公司股票交易异常波动的情况，公司董事会就相关事项进行了自查，并 向控股股东、实际控制人及其一致行动人进行了核实，现就有关情况说明如下： 1、公司前期所披露的信息，不存在需要更正、补充之处。 2、公司未发现近期公共媒体报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息。 3、近期公司经营情况及内外部经营环境未发生重大变化。 4、公司、控股股东和实际控制人不存在关于公司的应披露而未披露的重大 事项，或处于筹划阶段的重大事项。 ...

Investment Rating - The report assigns a "Buy" investment rating for the company, indicating a positive outlook for its stock performance in the next 12 months [9]. Core Viewpoints - The ongoing US-China trade tariff disputes have created opportunities for price increases in the company's main product, chlortetracycline, leading to both volume and price growth [2]. - The company holds a dominant position in the global chlortetracycline market, with a production capacity of 55,000 tons, accounting for approximately 50% of global capacity [2]. - The company is expected to benefit from a significant increase in sales in the US market, with a projected revenue growth of 32% year-on-year for its US subsidiary in the first three quarters of 2024 [2]. - The company plans to expand its product offerings, including a new chlortetracycline premix for sheep, which is expected to add over 20,000 tons in sales volume [3]. - The company has initiated a new production project that will add 60,000 tons of veterinary chemical capacity, further enhancing its growth potential [3]. - The company's vaccine business is also expected to grow, with a 3.75% increase in domestic vaccine revenue and an 18.29% increase in the US market [7]. - The environmental business segment is showing steady growth, with a 13.71% increase in revenue in the first half of 2024, contributing positively to overall profitability [8]. - Revenue forecasts for the company are projected to be 2.364 billion, 2.836 billion, and 3.398 billion yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 0.19, 0.26, and 0.39 yuan [11]. Summary by Sections Market Dynamics - The US has imposed a total tariff increase of 104% on Chinese goods, which has implications for the company's export pricing strategy [1]. - The company is leveraging its market position to implement price increases for its chlortetracycline products in the US market [2]. Product Development - The company is expanding its product line with new veterinary vaccines and chlortetracycline products, which are expected to drive future revenue growth [7][3]. - The introduction of a new brucellosis vaccine is anticipated to become a core product in the vaccine segment [7]. Financial Performance - The company is projected to see significant revenue growth driven by its chlortetracycline and vaccine businesses, alongside its environmental segment [9][11]. - The forecasted growth rates for revenue and net profit indicate a strong upward trend, with net profit expected to grow by 68.5% in 2024 [11].